38 results about "Ischemia-modified albumin" patented technology

It is a detecting ischemia modified albumin (IMA) reagent kit and detection method, and the reagent kit contains different division to remove the background interference material device, which can be centrifugal ultrafiltration IMA detection reagent kit, immunomagnetic beads IMA detection reagent kit, immunochromatography IMA detection reagent kit, immune chromatography membrane IMA detection board reagent kit or immune membrane filtration plate IMA detection reagent kit. After division removal of the background interference material, it can enhance the specific of detection IMA reagent kit and detection method, and using this reagent kit and hospital existing equipments, in about half an hour, it can measure the IMA value to diagnosis myocardial ischemia symptoms. Particularly suitable for bedside rapid detection kit development, ease to use, low cost, it is a very development promising product.

The invention discloses a kit for detecting ischemia modified albumin. The kit consists of a reagent 1 and a reagent 2. A surfactant is added to accelerate the reaction of the ischemia modified albumin; and a protective agent is selected to ensure the stability of the reagents. The kit has the better clinical application prospect. The invention further provides a preparation method of the kit.

The invention discloses an ischemia modified albumin liquid stabilization kit. The kit is a liquid dual reagent of a reagent 1 and a reagent 2, wherein the reagent 1 comprises a buffer solution of which the pH is 7.5 to 8.5 and the concentration is 0.05 to 0.5M, cobalt chloride at the concentration of 20 to 200mg/L, an interference removing agent at the concentration of 0.1 to 10g/L, a stabilizing agent at the concentration of 0.1 to 10g/L, and preservative at the concentration of 0.1 to 10g/L; and the reagent 2 comprises a buffer solution of which the pH is 7.0-8.0 and the concentration is 0.5 to 10M, dithiothreitol at the concentration of 0.5 to 50g/L, a stabilizing agent at the concentration of 0.1 to 10g/L, and preservative at the concentration of 0.1 to 10g/L. The kit has the advantages of fully meeting the clinical inspection requirement, along with high accuracy and stability, and can be stabilized for 12 months when stored at the temperature of between 2 and 8 DEG C in a dark place.

The invention discloses a stable ischemia modified albumin testing kit which comprises a cobalt ion reagent and a dithiothreitol (DTT) reagent. A small amount of nonionic surfactant is added in the dithiothreitol reagent, thus the combination of DTT in the reagent and free oxygen is greatly reduced, the oxidation speed of DTT is reduced, and the stability of the reagent is remarkably improved. Simultaneously, the concentration of DTT is increased, thus the stability of the kit is improved to a certain extent. The stable ischemia modified albumin testing kit disclosed by the invention can be stored stably in an opened bottle in a dark place at the room temperature for 30 days, and also can be stored stably in a closed bottle at the temperature of 2 to 8 DEG C for 12 months, and can totally meet the requirements for clinical examinations.

The invention relates to a steady ischemia modified albumin kit, which comprises a cobalt ion reagent and a dithiothreitol reagent, wherein the cobalt ion reagent comprises the following components: 50-500 mmol/L of buffer solution, 0.01-1.0 g/L of cobalt chloride, 1 g/L of surface active agent, and 0.5 g/L of preservative; and the dithiothreitol reagent comprises the following components: 50-300 mmol/L of buffer solution, 0.01-1.0 g/L of dithiothreitol (DTT), 1 g/L of surface active agent, 1-20 g/L of protective agent, and 0.5 g/L of preservative. The kit disclosed by the invention can reach reaction endpoint rapidly and is steady in property; after being opened, the kit can be stably stored in a dark place at room temperature for 30 days; after being closed, the kit can be stably stored at 2 DEG C -8 DEG C for 12 months, and therefore, clinical test requirements can be completely satisfied.

The invention discloses a preparation method of quality control serum for ischemia-modified albumin; the preparation method comprises the following steps of: (1) adopting the blood serum of a healthy person, and adjusting a pH value to be 7.0-7.5; (2) adding 0.1-100mm of metal ionic salt with a variable valence center or a metal organic composite with molecule planarity to the blood serum, and then adding 0.1-100mm of hydrogen peroxide; (3) reacting for 10-30min under the 35-40 DEG C illumination; (4) dialyzing a solution obtained through the reaction in the step (3) in 0.1-1000mm of a dialysis buffer solution with pH of 7.5-8.0 under the 20-25 DEG C temperature for 12-24h; and (5) adding a preservative according to a conventional technology, subpackaging and determining after mixing uniformly. The preparation method has the advantages of adequate the source of raw materials, easily obtaining of the raw materials, simple preparation technology, few amount of additives, low production cost, small non-specificity interference, no needing for composite dissolving, good homogeneity and small difference between bottles.

The invention discloses an ischemic heart disease detection kit and application thereof. The kit comprises a human serum albumin (HSA) primary antibody, an HAS secondary antibody compound coupled with QD, Co <2+> and a phosphate buffer solution (PBS) buffering solution. By the kit provided by the invention, a real ischemia modified albumin (IMA) value can be accurately detected, and the interference of ultrahigh or ultralow total HSA concentration is avoided; the detection can be completed within 20-30 minutes at high speed; the kit is particularly suitable for a biological indicator which needs to obtain a result quickly, such as the IMA.

The invention relates to the field of biotechnologies, and discloses a detection kit for ischemia modified albumin and a preparation method of the detection kit. The kit comprises a reagent R1and a reagent R2, wherein stabilizing agents of the R2 comprise ethanolamine, a nonionic surfactant and 2,2'-diethylamino dithio dihydrochloride, and the massic volume of ethanolamine is 20%-80%. According to the preparation method, by adding ethanolamine, the nonionic surfactant and 2,2'-diethylamino dithio dihydrochloride into the reagent R2, dithiothreitol (DTT) in the reagent R2 of the kit can not be easily oxidized and is long in half-life period, therefore, the detection kit for the ischemia modified albumin is high in stability, good in sample correlation and high in anti-jamming capability.

The subject application comprises methods for determining the occurrence of an ischemic event in a subject by determining an ischemia score based on the amount of at least two ischemia modified albumin markers. The ischemia modified albumin markers include complexes of fatty acids bound to albumin, albumin molecules with open Cys34 sites, albumin molecules that are products of oxidation at Cys34, albumin molecules with altered conformation or altered divalent metal binding due to the conformational change or oxidation at Cys34, and albumin molecules that have been oxidized at the N-terminus. Also included in the invention are ligands to each of the foregoing ischemia modified albumin markers. Further included are methods of determining the occurrence of an ischemic event by determining the amount of fatty acid that is complexed to albumin in a patient sample. In another embodiment, an ischemic event is determined by quantitating the relative amounts of reduced and oxidized forms of albumin Cys34. In an additional embodiment, an ischemic event is determined by observing whether a shift in albumin conformation has occurred which would reflect oxidized Cys34. Further, the invention comprises a method of determining an ischemic event by determining the amount of metal ion bound to the albumin metal ion binding sites.

The invention relates to a detection kit of ischemia modified albumins. The kit concretely comprises cobalt ions and dithiothreitol. A stabilizer is added to the kit, so the storage stability of the kit is increased; and a solubilizer is also added, so pollution of reagents to a colorimetric device is removed.

The invention relates to a reagent for quantitatively detecting the content of ischemia modified albumin in human serum. The reagent comprises a reagent I and a reagent II which are respectively placed, wherein the reagent I comprises sodium dihydrogen phosphate, disodium hydrogen phosphate and cobalt chloride, and the reagent II comprises sodium dihydrogen phosphate, disodium hydrogen phosphate and dithiothreitol. The kit and the detection method only need dozens of microlitres of serum without centrifugal or electrophoresis and other separation treatments, is simple and convenient to operate, can be used for meeting the requirement of full-automatic analysis, and are suitable for timely accurate detection of large-scale samples.

A method for assessing liver function in an individual, which method comprises determining the level of methylarginine(s) (such as ADMA and/or SDMA) and the ratio of ischemia modified albumin (IMA):albumin ratio (IMAR) in the individual, thereby to assess liver function in the individual.

The invention belongs to the technical field of medical examination, and in particular relates to a kit for rapidly detecting ischemia modified albumin and application of the kit. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 mainly consists of a glycine-sodium hydroxide buffer solution, cobalt chloride, hexadecyl trimethyl ammonium chloride and a preservative; and the reagent R2 mainly consists of a trihydroxymethyl aminomethane buffer solution, alpha-pyridine azo-beta-naphthol, hexadecyl trimethyl ammonium chloride, dipotassium phosphate, a stabilizing agent and a preservative. The kit for rapidly detecting ischemia modified albumin, which is provided by the invention, is high in detection result precision, good in repeatability and good in interference resistance, also has the advantages of being good in stability, low in price and easy to preserve, is a relatively ideal ischemia modified albumin detection kit, and is beneficial to clinical application of kits for rapidly detecting ischemia modified albumin.

The invention discloses an ischemia modified albumin determination colour-developing agent and a preparation method thereof. The preparation method comprises the steps of: taking 0.8-3.6 parts of 1-nitroso-2-naphthol and 1.2-3.5 parts of sodium hydroxide, dissolving in 100ml of purified water, and preparing into a solution A; taking 0.5-4.0 parts of citric acid, dissolving into 100ml of purified water, and preparing into a solution B; and blending the solution A with the solution B until the pH reaches 7.50-10.00, and preparing into a solution C; taking 100ml of solution C, taking 0.5-3.0 parts of fructose, 0.05-0.5 part of Tween 20 and 0.01-0.06 part of Proclin 300, adding into the solution C, uniformly stirring, and preparing into the ischemia modified albumin determination colour-developing agent. The invention has the advantages that the ischemia modified albumin determination colour-developing agent can be used for detecting ischemia modified albumin more sensitively, components of the ischemia modified albumin are common and are lower in price; and the whole preparation is more convenient and the preparation procedure is simple and easy to operate.

The invention provides an ischemia modified albumin calibrator and application thereof. The calibrator comprises a horizontal reagent 1 and a horizontal reagent 2. Each of the horizontal reagent 1 andthe horizontal reagent 2 is made of raw materials including ethylene diamine tetraacetic acid, sodium azide, sodium chloride and 3-(N-morpholino) propanesulfonic acid. According to the invention, onthe basis of the reaction principle of the ischemia modified albumin, a novel technology is established; the calibrator is prepared by using chelating agents like the EDTA to achieve the objective andthe traditional calibration formula is abandoned; compared with the traditional technology, the novel formula has advantages of high efficiency and stability and simple preparation; and the cost is lowered. Therefore, the ischemia modified albumin calibrator has the broad application prospects and great market value.

The invention provides a method for detecting ischemia modified albumin. According to the method, the characteristic that the binding capacity of the ischemic modified albumin and the cobalt is weakened is utilized, free cobalt in a reaction system is detected by using chemical reagents, the change of the content of the free cobalt is expressed through the change of absorbance, the concentration of the ischemia modified albumin is indirectly expressed, and a color developing agent used in the detection is 2,4-dimercaptopyrimidine and is used for detecting the free cobalt in the reaction system. The method has the advantages that the stability of the color developing agent of the 2,4-dimercaptopyrimidine is higher, the analysis sensitivity is higher, the price is lower, the detection resultis reported based on the concentration of the free cobalt, and the problem that the absorbance of an IMA (ischemia modified albumin) detection result is unstable due to the fact that the performanceof instruments or reagents is different and unstable when the absorbance is adopted for report can be solved. The invention further provides a detection kit for the ischemia modified albumin. The detection kit comprises the reagents used in the method.